JP2016501249A - ドコサペンタエン酸を含む組成物の投与 - Google Patents

ドコサペンタエン酸を含む組成物の投与 Download PDF

Info

Publication number
JP2016501249A
JP2016501249A JP2015545896A JP2015545896A JP2016501249A JP 2016501249 A JP2016501249 A JP 2016501249A JP 2015545896 A JP2015545896 A JP 2015545896A JP 2015545896 A JP2015545896 A JP 2015545896A JP 2016501249 A JP2016501249 A JP 2016501249A
Authority
JP
Japan
Prior art keywords
dpa
composition
dha
acid
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015545896A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501249A5 (OSRAM
Inventor
ジョージ ボボタス
ジョージ ボボタス
アブダル アジズ ファウジー
アブダル アジズ ファウジー
Original Assignee
マティナス バイオファーマ インコーポレイテッド
マティナス バイオファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マティナス バイオファーマ インコーポレイテッド, マティナス バイオファーマ インコーポレイテッド filed Critical マティナス バイオファーマ インコーポレイテッド
Publication of JP2016501249A publication Critical patent/JP2016501249A/ja
Publication of JP2016501249A5 publication Critical patent/JP2016501249A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B20/00—Preservation of edible oils or fats
    • A23B20/30—Preservation of other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B5/00—Preserving by using additives, e.g. anti-oxidants
    • C11B5/0007—Organic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
JP2015545896A 2012-12-06 2013-12-06 ドコサペンタエン酸を含む組成物の投与 Pending JP2016501249A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734331P 2012-12-06 2012-12-06
US61/734,331 2012-12-06
US201361780948P 2013-03-13 2013-03-13
US61/780,948 2013-03-13
PCT/US2013/073714 WO2014089511A2 (en) 2012-12-06 2013-12-06 Methods of administering compositions comprising docosapentaenoic acid

Publications (2)

Publication Number Publication Date
JP2016501249A true JP2016501249A (ja) 2016-01-18
JP2016501249A5 JP2016501249A5 (OSRAM) 2017-01-26

Family

ID=50884050

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015545894A Expired - Fee Related JP6881893B2 (ja) 2012-12-06 2013-12-06 ω３ペンタエン酸組成物および使用方法
JP2015545896A Pending JP2016501249A (ja) 2012-12-06 2013-12-06 ドコサペンタエン酸を含む組成物の投与
JP2019114492A Pending JP2019172697A (ja) 2012-12-06 2019-06-20 ω３ペンタエン酸組成物および使用方法
JP2021084578A Pending JP2021120407A (ja) 2012-12-06 2021-05-19 ω３ペンタエン酸組成物および使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015545894A Expired - Fee Related JP6881893B2 (ja) 2012-12-06 2013-12-06 ω３ペンタエン酸組成物および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019114492A Pending JP2019172697A (ja) 2012-12-06 2019-06-20 ω３ペンタエン酸組成物および使用方法
JP2021084578A Pending JP2021120407A (ja) 2012-12-06 2021-05-19 ω３ペンタエン酸組成物および使用方法

Country Status (9)

Country Link
EP (3) EP2928462A4 (OSRAM)
JP (4) JP6881893B2 (OSRAM)
KR (3) KR20210059779A (OSRAM)
CN (4) CN112107570A (OSRAM)
AU (7) AU2013354979A1 (OSRAM)
CA (2) CA2894366A1 (OSRAM)
IN (2) IN2015MU01505A (OSRAM)
MX (2) MX2015007082A (OSRAM)
WO (2) WO2014089511A2 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101568665B1 (ko) 2015-07-21 2015-11-12 디와이오토 주식회사 모터의 맥동 전류를 증가시키는 브러시 구조
CN109313202A (zh) * 2016-06-28 2019-02-05 雀巢产品技术援助有限公司 血脑屏障功能障碍的生物标志物
JP2018168139A (ja) * 2016-10-21 2018-11-01 マルハニチロ株式会社 ｎ−３系不飽和脂肪酸を含む中性脂肪値の低減または上昇抑制用の組成物、並びに該組成物の製造におけるｎ−３系不飽和脂肪酸の使用
JP7099821B2 (ja) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002125618A (ja) * 2000-10-30 2002-05-08 Katsuyuki Wakatsuki 健康食品

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
NZ573719A (en) * 2006-07-05 2011-08-26 Photonz Corp Ltd Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis
KR100684642B1 (ko) * 2006-09-14 2007-02-22 주식회사 일신웰스 어유 유래 글리세라이드 유지 조성물 및 이의 제조방법
AU2010222648B2 (en) * 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
SMT201800047T1 (it) * 2009-04-29 2018-03-08 Amarin Pharmaceuticals Ie Ltd Composizione farmaceutica stabile e metodi di utilizzo della stessa
KR102012111B1 (ko) * 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
CA2827555A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
JP2014505732A (ja) * 2011-02-16 2014-03-06 ピヴォタル セラピューティクス インコーポレイテッド 心血管疾患において用いるための、スタチンおよびω３脂肪酸（ＥＰＡ、ＤＨＡおよびＤＰＡ）
AU2013277441B2 (en) * 2012-06-17 2017-07-06 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002125618A (ja) * 2000-10-30 2002-05-08 Katsuyuki Wakatsuki 健康食品

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ATHEROSCLEROSIS, vol. 221, JPN6017037664, April 2012 (2012-04-01), pages 397 - 404, ISSN: 0003943277 *
LIPIDS, vol. 45, JPN7017003163, 2010, pages 669 - 681, ISSN: 0003943276 *

Also Published As

Publication number Publication date
JP6881893B2 (ja) 2021-06-02
AU2017232203A1 (en) 2017-10-12
AU2019216634A1 (en) 2019-09-05
JP2019172697A (ja) 2019-10-10
KR20150103671A (ko) 2015-09-11
AU2013354979A1 (en) 2015-06-11
MX2015007082A (es) 2016-01-12
AU2020203658A1 (en) 2020-06-25
AU2021201865A1 (en) 2021-04-22
EP2928462A2 (en) 2015-10-14
IN2015DE05009A (OSRAM) 2015-12-18
CN113274378A (zh) 2021-08-20
CN112107570A (zh) 2020-12-22
EP2929041A4 (en) 2016-06-08
KR20210059779A (ko) 2021-05-25
WO2014089511A2 (en) 2014-06-12
AU2018229440A1 (en) 2018-10-04
MX2015007085A (es) 2016-01-12
EP3888646A1 (en) 2021-10-06
CN104902888A (zh) 2015-09-09
EP2929041A1 (en) 2015-10-14
WO2014089511A3 (en) 2014-07-31
CA2894183A1 (en) 2014-06-12
CN104937103A (zh) 2015-09-23
CA2894366A1 (en) 2014-06-12
WO2014089501A1 (en) 2014-06-12
JP2021120407A (ja) 2021-08-19
IN2015MU01505A (OSRAM) 2016-05-27
EP2928462A4 (en) 2016-06-01
KR20150103009A (ko) 2015-09-09
JP2016501248A (ja) 2016-01-18
AU2013354969A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
US20210205254A1 (en) Omega-3 pentaenoic acid compositions and methods of use
JP2019172697A (ja) ω３ペンタエン酸組成物および使用方法
CN106074486A (zh) 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
WO2014179341A1 (en) Treatment with omega-3 fatty acid compositions
JP2016512544A (ja) ドコサペンタエン酸を含む組成物、および使用方法
US20140194512A1 (en) Compositions comprising docosapentaenoic acid and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181012

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20181101

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20181221